The Radiologically Isolated Syndrome: Look (Again) Before You Treat



The advent and wide use of magnetic resonance brain imaging has led to in the unexpected detection of lesions that appear typical of multiple sclerosis (MS) in otherwise asymptomatic patients. Several cohorts of patients with the “radiologically isolated syndrome (RIS)” have been studied mainly retrospectively, and a proportion of them do go on to have clinical symptoms of MS. This has led to the not infrequent clinical conundrum of whether or not to treat patients with MRI lesions suggestive of MS, given the knowledge that MS disease-modifying therapies work best when given early in the disease course. However, the decision to proactively treat patients with RIS is countered by the increasing risks associated with MS disease-modifying therapies as well as the uncertain prognostic outcome of RIS. This review will highlight what is and is not known about the long-term outcomes of RIS and present recommendations for clinicians when faced with this challenging situation.


Multiple sclerosis/diagnosis Multiple sclerosis/therapy Magnetic resonance imaging Incidental findings Brain/pathology Disease progression Radiologically isolated syndrome 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group: PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56(12):1628–36.Google Scholar
  2. 2.
    Uitdehaag B, Constantinescu C, Cornelisse P, et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord. 2011;4(1):3–14.PubMedCrossRefGoogle Scholar
  3. 3.
    Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227–31.PubMedCrossRefGoogle Scholar
  4. 4.
    Paty DW, Oger JJ, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology. 1988;38(2):180–5.PubMedGoogle Scholar
  5. 5.
    Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357(9268):1576–82.PubMedCrossRefGoogle Scholar
  6. 6.
    Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343(13):898–904.PubMedCrossRefGoogle Scholar
  7. 7.
    Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Lyoo IK, Seol HY, Byun HS, Renshaw PF. Unsuspected multiple sclerosis in patients with psychiatric disorders: a magnetic resonance imaging study. J Neuropsychiatry Clin Neurosci. 1996;8(1):54–9.PubMedGoogle Scholar
  9. 9.
    •• Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 2009;72(9):800–5. This study named and proposed diagnostic criteria for the RIS, and described the outcomes of a small cohort of patients with this condition. PubMedCrossRefGoogle Scholar
  10. 10.
    Sellner J, Schirmer L, Hemmer B, Muhlau M. The radiologically isolated syndrome: take action when the unexpected is uncovered? J Neurol. 2010;257(10):1602–11.PubMedCrossRefGoogle Scholar
  11. 11.
    Mackay RP, Hirano A. Forms of benign multiple sclerosis. Report of two “clinically silent” cases discovered at autopsy. Arch Neurol. 1967;17(6):588–600.PubMedGoogle Scholar
  12. 12.
    Morariu M, Klutzow WF. Subclinical multiple sclerosis. J Neurol. 1976;213(1):71–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Castaigne P, Lhermitte F, Escourolle R, Castaigne P, Lhermitte F, Escourolle R, et al. Asymptomatic multiple sclerosis—3 cases (author’s transl). Rev Neurol (Paris). 1981;137(12):729–39.Google Scholar
  14. 14.
    Gilbert JJ, Sadler M. Unsuspected multiple sclerosis. Arch Neurol. 1983;40(9):533–6.PubMedGoogle Scholar
  15. 15.
    Engell T. A clinical patho-anatomical study of clinically silent multiple sclerosis. Acta Neurol Scand. 1989;79(5):428–30.PubMedCrossRefGoogle Scholar
  16. 16.
    Heinsen H, Lockemann U, Puschel K. Unsuspected (clinically silent) multiple sclerosis. Quantitative investigations in one autoptic case. Int J Legal Med. 1995;107(5):263–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Barkhof F, Scheltens P, Kamphorst W. Pre-and post-mortem MR imaging of unsuspected multiple sclerosis in a patient with Alzheimer’s disease. J Neurol Sci. 1993;117(1–2):175–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Lycklama à Nijeholt G, Barkhof F. Differences between subgroups of MS: MRI findings and correlation with histopathology. J Neurol Sci. 2003;206(2):173–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Seewann A, Kooi EJ, Roosendaal SD, et al. Translating pathology in multiple sclerosis: the combination of postmortem imaging, histopathology and clinical findings. Acta Neurol Scand. 2009;119(6):349–55.PubMedCrossRefGoogle Scholar
  20. 20.
    Herndon RM, Rudick RA. Multiple sclerosis: the spectrum of severity. Arch Neurol. 1983;40(9):531–2.PubMedGoogle Scholar
  21. 21.
    Wasay M, Rizvi F, Azeemuddin M, et al. Incidental MRI lesions suggestive of multiple sclerosis in asymptomatic patients in Karachi, Pakistan. J Neurol Neurosurg Psychiatry. 2011;82(1):83–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Traboulsee AL, Li DK. The role of MRI in the diagnosis of multiple sclerosis. Adv Neurol. 2006;98:125–46.PubMedGoogle Scholar
  23. 23.
    de Seze J, Vermersch P. Sequential magnetic resonance imaging follow-up of multiple sclerosis before the clinical phase. Mult Scler. 2005;11(4):395–7.PubMedCrossRefGoogle Scholar
  24. 24.
    McDonnell GV, Cabrera-Gomez J, Calne DB, et al. Clinical presentation of primary progressive multiple sclerosis 10 years after the incidental finding of typical magnetic resonance imaging brain lesions: the subclinical stage of primary progressive multiple sclerosis may last 10 years. Mult Scler. 2003;9(2):204–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120(Pt 11):2059–69.PubMedCrossRefGoogle Scholar
  26. 26.
    Lebrun C, Bensa C, Debouverie M, et al. Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. J Neurol Neurosurg Psychiatry. 2008;79(2):195–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Tintore M, Rovira A, Martinez MJ, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol. 2000;21(4):702–6.PubMedGoogle Scholar
  28. 28.
    •• Okuda DT, Mowry EM, Cree BA, et al. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology 2011;76(8):686–92. This study indicates that it may be possible to risk stratify patients with RIS based on lesion location. Further risk stratification will be important when deciding on therapeutic intervention for RIS. PubMedCrossRefGoogle Scholar
  29. 29.
    Bourdette D, Yadav V. The radiologically isolated syndrome revisited: when is it presymptomatic multiple sclerosis? Neurology. 2011;76(8):680–1.PubMedCrossRefGoogle Scholar
  30. 30.
    Siva A, Saip S, Altintas A, et al. Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease. Mult Scler. 2009;15(8):918–27.PubMedCrossRefGoogle Scholar
  31. 31.
    Sierra-Marcos A, Mitjana R, Castillo J, et al. Demyelinating lesions as incidental findings in magnetic resonance imaging: a study of 11 cases with clinico-radiological follow-up and a review of the literature. Rev Neurol. 2010;51(3):129–34.PubMedGoogle Scholar
  32. 32.
    Schumacker GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci. 1965;122:552–68.PubMedCrossRefGoogle Scholar
  33. 33.
    CHAMPS Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology. 2002;59(7):998–1005.Google Scholar
  34. 34.
    McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58(6):840–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.PubMedCrossRefGoogle Scholar
  37. 37.
    Swanton JK, Rovira A, Tintore M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol. 2007;6(8):677–86.PubMedCrossRefGoogle Scholar
  38. 38.
    Swanton JK, Fernando K, Dalton CM, et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry. 2006;77(7):830–3.PubMedCrossRefGoogle Scholar
  39. 39.
    Rolak LA, Fleming JO. The differential diagnosis of multiple sclerosis. Neurologist. 2007;13(2):57–72.PubMedCrossRefGoogle Scholar
  40. 40.
    Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124–40.PubMedCrossRefGoogle Scholar
  41. 41.
    Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372(9648):1463–72.PubMedCrossRefGoogle Scholar
  42. 42.
    • Chard DT, Dalton CM, Swanton J, et al. MRI only conversion to multiple sclerosis following a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 2011;82(2):176–9. This looks at the long-term outcomes of CIS, which are important when conducting risk/benefit considerations of MS therapies in early stages of disease. PubMedCrossRefGoogle Scholar
  43. 43.
    Charil A, Yousry TA, Rovaris M, et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation”. Lancet Neurol. 2006;5(10):841–52.PubMedCrossRefGoogle Scholar
  44. 44.
    Korteweg T, Uitdehaag BM, Knol DL, et al. Interobserver agreement on the radiological criteria of the International Panel on the diagnosis of multiple sclerosis. Eur Radiol. 2007;17(1):67–71.PubMedCrossRefGoogle Scholar
  45. 45.
    Seewann A, Enzinger C, Filippi M, et al. MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain: a review of reported findings. J Neurol. 2008;255(1):1–10.PubMedCrossRefGoogle Scholar
  46. 46.
    Lebrun C, Blanc F, Brassat D, et al. CFSEP: cognitive function in radiologically isolated syndrome. Mult Scler. 2010;16(8):919–25.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC (outside the USA) 2011

Authors and Affiliations

  1. 1.Department of NeurologyOregon Health & Science UniversityPortlandUSA
  2. 2.Neurology ServicePortland VA Medical CenterPortlandUSA

Personalised recommendations